Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$0.22 - $0.5 $10,400 - $23,638
-47,277 Reduced 13.55%
301,596 $90,000
Q2 2023

Aug 15, 2023

BUY
$0.35 - $0.56 $31 - $50
90 Added 0.03%
348,873 $143,000
Q1 2023

May 12, 2023

SELL
$0.36 - $0.63 $6,403 - $11,205
-17,787 Reduced 4.85%
348,783 $129,000
Q4 2022

Feb 13, 2023

BUY
$0.41 - $1.1 $23,588 - $63,286
57,533 Added 18.62%
366,570 $175,000
Q3 2022

Nov 14, 2022

BUY
$0.57 - $1.77 $95,478 - $296,487
167,507 Added 118.35%
309,037 $265,000
Q2 2022

Aug 12, 2022

SELL
$0.85 - $1.41 $49,639 - $82,342
-58,399 Reduced 29.21%
141,530 $132,000
Q1 2022

May 16, 2022

BUY
$1.16 - $2.5 $46,123 - $99,405
39,762 Added 24.83%
199,929 $264,000
Q4 2021

Feb 14, 2022

SELL
$2.46 - $8.74 $47,615 - $169,171
-19,356 Reduced 10.78%
160,167 $394,000
Q3 2021

Nov 15, 2021

SELL
$5.1 - $9.39 $26,647 - $49,062
-5,225 Reduced 2.83%
179,523 $1.53 Million
Q2 2021

Aug 16, 2021

SELL
$3.95 - $6.88 $230,340 - $401,200
-58,314 Reduced 23.99%
184,748 $1.18 Million
Q1 2021

May 13, 2021

BUY
$2.01 - $5.55 $44,947 - $124,109
22,362 Added 10.13%
243,062 $1.08 Million
Q4 2020

Feb 09, 2021

BUY
$1.73 - $2.13 $154,772 - $190,558
89,464 Added 68.17%
220,700 $468,000
Q3 2020

Nov 05, 2020

BUY
$1.76 - $2.17 $139,363 - $171,829
79,184 Added 152.12%
131,236 $234,000
Q2 2020

Aug 13, 2020

BUY
$1.75 - $2.65 $90,867 - $137,598
51,924 Added 40565.63%
52,052 $110,000
Q1 2020

May 14, 2020

BUY
$1.15 - $3.29 $147 - $421
128 New
128 $0

Others Institutions Holding PAVM

# of Institutions
1
Shares Held
2.24M
Call Options Held
0
Put Options Held
0

About PAVmed Inc.


  • Ticker PAVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 90,999,104
  • Market Cap $74.6M
  • Description
  • PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted ne...
More about PAVM
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.